Quivive Pharma has entered into service agreements with Camargo Pharmaceutical Services. Camargo will provide regulatory consulting and strategic development services for Quivive's pipeline of fixed-dose combination products built upon its patented abuse-deterrent and misuse-prevention technology platform. The first program will concentrate on an abuse-deterrent immediate-release 505(b)(2) combination of hydrocodone and an approved respiratory stimulant.
"As a practicing anesthesiologist for 28 years, I have seen the dangers of opioid overdose and drug-induced respiratory depression firsthand," Quivive Pharma CEO, John Hsu said. "Quivive is the first company to specifically focus on reducing or eliminating the dangers of respiratory depression in existing therapeutics based on the concept of functional antagonism via novel combination products. We are confident that we can make these critical medicines safer, and do so in a way that is both efficient and cost effective."
"One longtime concern has been to find a way to prevent opioid abuse," Ken Phelps, CEO of Camargo Pharmaceutical Services said. "We are excited to work on this solution to the crisis and have a hand in the effort of saving many lives worldwide."